Skip to content
Screener

Kalaris Therapeutics KLRS Q1 2026 earnings

Reported May 12, 2026 · Before market open

EPS-$0.46Beat by $0.06
EPS estimate-$0.52

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.52

Financials

Q1 2026

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M—
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$132.3M—
Enterprise value$99.28M—

Returns & leverage

See full
Return on equity-66.6%—
Debt / equity0×—
Current ratio12.2×-2.1×

FAQ

When did Kalaris Therapeutics report Q1 2026 earnings?
Kalaris Therapeutics (KLRS) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Kalaris Therapeutics's Q1 2026 revenue and EPS?
Kalaris Therapeutics reported eps of $-0.46 for Q1 2026.
Did Kalaris Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.52 by $0.06.
How did Kalaris Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 81.7% from $-2.52.
Where can I find Kalaris Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-218240) and the 10-Q periodic report (0001193125-26-219328) directly on SEC EDGAR. The filing index links above go to sec.gov.